期刊
EUROPEAN JOURNAL OF CANCER
卷 45, 期 3, 页码 335-346出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2008.12.008
关键词
Gene methylation; Cancer; Biomarkers; Tumour markers; Pathobiology group; EORTC
类别
资金
- European Union [LSHC-CT-2003-504586]
Aberrant hypermethylation of promoter regions in specific genes is a key event in the formation and progression of cancer. In at least some situations, these aberrant alterations occur early in the formation of malignancy and appear to be tumour specific. Multiple reports have suggested that measurement of the methylation status of the promoter regions of specific genes can aid early detection of cancer, determine prognosis and predict therapy responses. Promising DNA methylation biomarkers include the use of methylated GSTP1 for aiding the early diagnosis of prostate cancer, methylated PITX2 for predicting outcome in lymph node-negative breast cancer patients and methylated MGMT in predicting benefit from alkylating agents in patients with glioblastomas. However, prior to clinical utilisation, these findings require validation in prospective clinical studies. Furthermore, assays for measuring gene methylation need to be standardised, simplified and evaluated in external quality assurance programmes. it is concluded that methylated genes have the potential to provide a new generation of cancer biomarkers. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据